HOME >> BIOLOGY >> NEWS
Growth disorder gene plays a big role in normal size variation

The presence of a small number of discrete forms - as you find in a classic Mendelian trait like eye color - suggests that the phenotype is controlled by a very small number of genes. In contrast, a complex trait such as body size is influenced by multiple genes as well as environmental factors, giving rise to a continuous spectrum of phenotypes. This causal complexity makes discovery of the genetic determinants of the trait - so-called quantitative trait loci (QTLs) - very difficult. In the open-access journal PLoS Biology, Fiona Oliver, Julian Christians, and colleagues extend their work on a single QTL with a large effect on body size variation in mice, and show that the responsible gene is one already linked to a Mendelian growth disorder in humans.

In this study, the authors further refined the map of a QTL on the X chromosome associated with a 20% difference in growth rate of mice, and found it contains only four genes: glypican-3 and glypican-4 (Gpc3 and Gpc4), and two other genes of unknown function. The glypicans are membrane-bound growth regulators; loss of function of Gpc3 in humans causes a rare syndrome of overgrowth, skeletal and other abnormalities, and neonatal death. In Gpc3, but not the others, size correlated with a significant difference in gene expression: larger mice had low levels of the messenger RNA, and smaller mice had high levels - the same pattern seen in the human loss-of-function disorder. The authors identified several non-coding polymorphisms in Gpc3 that differed between the two forms, although it remains to be seen whether the differential effect on growth is due to these or other DNA differences nearby.

The results from this study point out an important feature of inheritance, namely, that a gene implicated in a Mendelian trait can also contribute to quantitative variation. While catastrophic expression failure, such as a loss of function, can cause disease, smaller changes in expression of the same
'"/>

Contact: Paul Ocampo
pocampo@plos.org
415-624-1224
Public Library of Science
4-Apr-2005


Page: 1 2

Related biology news :

1. Growth factors and environment combine to increase brain maturation
2. Growth factor signals influence balance between normal growth and cancerous growth
3. Growth factor triggers growth of new blood vessels in the heart
4. Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons
5. Growth hormone is made in the brain, report scientists
6. Growth hormone, obesity can trigger sleep apnea in some kids
7. Growth in biomass could put US on road to energy independence
8. Growth factor in baby formula could reduce NEC, most devastating GI disease in preemies
9. Growth in the sea comes down to a struggle for iron
10. Growth of common skin cancer blocked in gene-switch mice
11. Growth factors confer immortality to sperm-generating stem cells

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Growth disorder gene plays big role normal size variation

(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: